Comerica Hatch Detroit Contest by TechTown reveals 10 semifinalists vying for $100,000 grand prize
Top 10 entrepreneurs vie for $100,000 prize from Comerica Bank as public voting begins
DETROIT, May 15, 2025 /PRNewswire/ -- The Comerica Hatch Detroit Contest by TechTown, the small business competition behind many of Detroit's most popular neighborhood storefronts, is unveiling its Top 10 semifinalists. These entrepreneurs will go head-to-head over the coming weeks, competing to win $100,000 in startup funds from Comerica Bank to open a brick-and-mortar storefront in Detroit, Hamtramck or Highland Park.
Public voting to narrow the 10 semifinalists to four finalists begins Friday, May 16, at noon and runs through Friday, May 23, at 11:59 p.m. Community members can vote for their favorite businesses once per day by visiting HatchDetroit.com.
The four finalists of the 2025 Comerica Hatch Detroit Contest by TechTown will be revealed on Tuesday, May 27, with the final round of public voting beginning on Monday, June 2, at noon and running through the completion of the pitch competition at "Hatch Off" on Wednesday, June 11.
"The neighborhood voices of our community have long been instrumental in shaping Detroit's small business landscape, and the Comerica Hatch Detroit Contest by TechTown is no exception," said Christianne Malone, Assistant Vice President for Economic Development at Wayne State University and Chief Program Officer of TechTown Detroit. "This city's entrepreneurial spirit shines brightest when ignited by the passion of its people. Through this contest, we witness how strong community support can elevate a single storefront into a catalyst for neighborhood revitalization, and we're proud to be a proven launching pad for these small business owners."
Over the years, the Comerica Hatch Detroit Contest by TechTown has helped create some of Detroit's most successful and well-known businesses, including winners G.L.A.M Body Scrubs (2024), Bouncing Around The Motor City (2023), Little Liberia (2022), 27th Letter Books (2019), Baobab Fare (2017), Meta Physica Massage (2016), Sister Pie (2014), Batch Brewing Company (2013) and La Feria (2012).
Below are the Top 10 businesses competing to win the 2025 Comerica Hatch Detroit Contest:
The Coloring Museum: The Coloring Museum harnesses the power of the crayon to bring community collaboration, spark creativity, and promote mental wellness. Through vibrant events and interactive experiences, residents and guests color black-and-white murals illustrated by local artists. Each mural becomes a collective masterpiece, transforming simple lines into colorful stories celebrating connection, self-expression, and the healing power of art therapy.
Cone Vecinos: Every neighborhood should have a beloved ice cream shop. Cone Vecinos aspires to be an anchor for the Morningside community with a simple concept: soft serve ice cream + friends. Cone Vecinos will bring together all ages, all walks of life to enjoy a no-frills treat with neighbors and newcomers alike.
Detroit Culture & Clay: Detroit Culture & Clay is a one stop for all things clay. Guests can enjoy paint and sips, hands-on learning and a full stock of ceramic supplies, while also supporting local artists by purchasing their unique work.
Evelyn's Midtown Kitchen: Evelyn's Midtown Kitchen offers immersive, hands-on cooking classes that spark joy, build confidence, and foster community. From youth camps to date nights and global cuisine workshops, Evelyn's Midtown Kitchen defines their mission as serving Detroit and beyond with accessible, culturally rich experiences that create connection, celebrate diversity and make culinary education a joyful, empowering tool for community impact, growth, and meaningful engagement.
For the Love of Cheesecake: For the Love of Cheesecake crafts exceptional, fully customizable cheesecakes using premium, locally sourced ingredients, while uplifting the Detroit community through job creation and entrepreneurial support. Extending beyond cheesecakes, For the Love of Cheesecake empowers local women and students with flexible employment and fosters economic growth by providing shared commercial kitchen space to help emerging food entrepreneurs build and scale their businesses.
Halie & Co: Halie & Co is a handmade jewelry, candle, and home fragrance store with the belief that everyone should have access to affordable jewelry and goods that make them feel beautiful and are created with high-quality materials and intention. Halie & Co creates experiences through permanent jewelry and jewelry making workshops, giving customers the perfect way to be a part of the creation process.
Livy's Sweet Rolls: Livy's Sweet Rolls specializes in handcrafted gourmet cinnamon rolls made from scratch with nostalgic, high-quality ingredients. Inspired by a family tradition of wholesome baking, Livy's Sweet Rolls offers better-for-you desserts free from preservatives, dyes, and artificial junk. Its mission is to spread joy through premium sweet treats that families can trust, enjoy, and create memories around.
Que Shebley: Que Shebley is a luxury fashion brand founded by Lebanese-American designer Que Shebley. Merging heritage with innovation, the brand is launching a world-class flagship in downtown Detroit, a fusion of bespoke tailoring, cutting-edge tech, and a high-fashion café. From handcrafted shoes to custom suits, Que Shebley offers a bold new take on modern elegance and self-expression.
The Spiced Bar: The Spiced Bar is Detroit's first full-service flavor destination. Guests create custom spice blends, sip bold drinks at a spice-forward beverage bar, and explore globally inspired small bites—all in one immersive space. It's where curiosity meets culture, and flavor becomes a form of self-expression. Crafted for Detroit. Made to be unforgettable.
Walter Pat's Bakery Cafe: Walter Pat's Bakery Cafe is a seasonally driven, small-batch, black woman-owned bakery in Detroit. The cafe focuses on Michigan seasonal produce and specific flavors from Midwest upbringing and southern influence. Walter Pat's strives to showcase unique flavor combinations and delicious classics, as well as to broaden taste buds with a new experience through food.
With this year's contributions and grants, Comerica and Comerica Charitable Foundation have invested $1.3 million into Hatch Detroit since it first began supporting the small business program in 2012.
2025 Hatch Off
The contest will culminate with the annual "Hatch Off" where the Top 4 entrepreneurs present their business plans in front of a panel of expert judges and live audience. The winner of the 2025 Comerica Hatch Detroit Contest will be chosen through a combination of the public's vote and judges' deliberations.
Tickets are now available to witness the Top 4 business pitches and see the winner of the "Hatch Off" competition crowned. The "Hatch Off" takes place on Wednesday, June 11, at 6 p.m., at the Wayne State University Industry Innovation Center at 461 Burroughs Street in Detroit. To purchase your ticket to the "Hatch Off," visit HatchDetroit.com.
Comerica Bank, a subsidiary of Comerica Incorporated, has served Michigan longer than any other bank with a continuous presence dating back over 175 years to its Detroit founding in 1849. It is the largest bank employer in metro Detroit and has more than 4,300 employees (FTE) statewide. With one of the largest banking center networks in Michigan, Comerica nurtures lifelong relationships with unwavering integrity and financial prudence. Comerica positively impacts the lives of Michigan residents by helping customers be successful, providing financial support that assists hundreds of charitable organizations, and actively participating in Detroit's downtown revitalization. Comerica Incorporated (NYSE: CMA) is a financial services company strategically aligned by three business segments: The Commercial Bank, The Retail Bank, and Wealth Management. Follow on Facebook: www.facebook.com/Comerica, X: @ComericaBank and Instagram: @comerica_bank.
TechTown Detroit, Wayne State University's entrepreneurship hub, is a nonprofit business service organization that provides programs, education and resources for early- to growth-stage small businesses and tech entrepreneurs. By building bridges for entrepreneurs to succeed, TechTown is accelerating an inclusive economy for Detroit and Southeast Michigan. Since 2007, TechTown has supported more than 6,090 companies, which created 2,277 jobs and raised more than $406 million in startup and growth capital. For more information, visit techtowndetroit.org.
Hatch Detroit supports both existing and new retail initiatives in the cities of Detroit, Hamtramck and Highland Park. Hatch Detroit was founded in 2011 to give residents and aspiring entrepreneurs an opportunity to have a voice in neighborhood retail development and joined TechTown Detroit's suite of entrepreneurial programs and services in 2022. Beyond the contest, Hatch Detroit provides funding, exposure and mentoring in support of its alumni entrepreneurs. With support from Hatch Detroit, 50 alumni have opened businesses. They employ over 500 people and have invested over $10 million in economic development. To learn more, visit hatchdetroit.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/comerica-hatch-detroit-contest-by-techtown-reveals-10-semifinalists-vying-for-100-000-grand-prize-302457272.html
SOURCE Comerica Bank
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
12 hours ago
- Forbes
Medtronic Announces Intent To Spin Diabetes Business
(Photo Illustration by) Deal OverviewOn May 21, 2025, Medtronic plc (NYSE: MDT; $87.44, Market Capitalization: $112.1 billion), a global leader in medical technology, announced its intent to spin off its Diabetes business into a standalone entity (New Diabetes Company). This strategic move is designed to streamline Medtronic's portfolio, sharpen its focus on high-margin growth areas, and unlock shareholder value. Post spin-off, Medtronic (RemainCo) will continue to operate as a diversified MedTech innovator, concentrating on its core franchises in cardiovascular, neuroscience, surgical, and medical-surgical technologies. Further, the company aims to accelerate growth through innovation in areas like pulsed field ablation, renal denervation, soft tissue robotics, and neuromodulation. Meanwhile, the New Diabetes Company (NewCo) will be offering a complete ecosystem for intensive insulin management, including insulin pumps, continuous glucose monitoring (CGM), and digital health solutions. The separation is expected to be completed within 18 months, primarily through a capital markets transaction, with a preferred path of an initial public offering (IPO) followed by a split-off. The transaction is expected to be tax-free to Medtronic shareholders for US federal income tax purposes. The separation will include the Diabetes business employees, product portfolio, pipeline, intellectual property, strategic partnerships, and global manufacturing facilities. Medtronic Price Performance Spin-Off Details and Top 5 Shareholders The transaction is anticipated to be accretive to Medtronic's gross and operating margins, and earnings per share, while enabling the NewCo to pursue focused innovation and growth strategies tailored to the diabetes market. It is also expected to provide the ability to retire Medtronic shares outstanding without reducing cash, resulting in EPS accretion and a reduction in the dividend liability for Medtronic, enabling increased growth-accretive investment. Medtronic expects its dividend per share to remain unchanged pre- and post-transaction with no change to its dividend policy. The spin-off is subject to customary regulatory approvals, board consent, and market conditions. Que Dallara, current EVP and president of Medtronic Diabetes, will become CEO of New Diabetes Company. Goldman Sachs & Co. LLC and BofA Securities, Inc. are acting as financial advisors to Medtronic in its review of strategic alternatives for the New Diabetes Company. Key Data Deal Rationale Medtronic, a global leader in MedTech, is planning to spin off its Diabetes business into a standalone entity, as part of a strategic move to sharpen its focus on higher-margin, faster-growing segments such as Cardiovascular, Neuroscience, and Medical-Surgical, which together account for over 90.0% of its total revenues. The Diabetes segment, contributing approximately $2.5 billion in FY25 (about 8.0% of Medtronic's total $32.4 billion in revenue), has consistently underperformed over the past five years, with a revenue CAGR of just ~1.4% compared to Medtronic's overall ~2.9% CAGR. Segment profitability has also lagged: while Medtronic's overall operating margin stands at ~15.9%, the diabetes unit has been a drag, reportedly generating operating losses in the low teens in its core U.S. market. In FY19, the segment posted a strong operating margin of 30.9% but steadily declined to 24.8–24.9% through FY21 and FY22, before dropping significantly to 15.8% in FY25. Multiple headwinds contributed to this underperformance, including FDA regulatory setbacks, such as the 2021 warning letter and delayed approval of the MiniMed 780G insulin pump and Guardian 4 sensor, alongside intensifying competition from more agile players like Dexcom, Abbott, Tandem, and Insulet. These rivals outpaced Medtronic with faster innovation in continuous glucose monitoring (CGM) and closed loop insulin delivery systems. Furthermore, the rising adoption of GLP-1 receptor agonists (e.g., Ozempic, Mounjaro) is shifting treatment paradigms, particularly for Type 2 diabetes, reducing demand for insulin pumps. Despite a recent rebound, with the diabetes segment growing ~10.7% YoY in FY25 and six consecutive quarters of double-digit growth, the improvement is seen as insufficient to offset the structural challenges and lower returns relative to the rest of Medtronic's portfolio. By spinning off the diabetes business, Medtronic aims to lift its gross margin by approximately 50 basis points, adjusted operating margins by approximately 100 basis points, and be immediately accretive to adjusted EPS. As per management, following this separation, Medtronic is expected to increase focus on innovation-driven growth and category leadership for healthcare systems and physician customers. The company will have enhanced benefit from its scale and strategic commercial, manufacturing, and technology synergies. On the other hand, this separation is expected to enable more focused investment into New Diabetes Company's pipeline, as well as manufacturing scale and automation, positioning the company for success in Automated Insulin Delivery and Smart MDI, while driving margin expansion over time. At the same time, it will create an independent, scaled leader in Diabetes, focused on accelerating innovation and differentiated as the only company to commercialize a complete ecosystem to address intensive insulin management. The separation is also expected to unlock value for Medtronic and its shareholders, as it creates a New Diabetes Company shareholder base more aligned with its financial profile. Medtronic plc is a global healthcare technology leader that designs and manufactures medical devices and therapies to treat a wide range of chronic and acute health conditions. The company operates in over 150 countries and focuses on improving patient outcomes through innovation in areas such as AI, robotics, and data-driven care. Medtronic's operations are structured into four major segments, each addressing a distinct area of healthcare technology. The Cardiovascular segment includes heart rhythm devices, heart valves, and vascular therapies for treating cardiac and circulatory conditions. The Neuroscience segment offers spinal implants, stroke treatment devices, and neuromodulation systems for managing neurological and musculoskeletal disorders. The Medical Surgical segment provides surgical tools, robotic-assisted systems, and patient monitoring technologies, while the Diabetes segment delivers insulin pumps, continuous glucose monitoring systems, and smart insulin pens to help manage diabetes effectively. Cardiovascular: The Cardiovascular segment is dedicated to treating heart and vascular diseases through advanced medical technologies. It includes three subsegments: Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and Coronary & Peripheral Vascular. This segment offers pacemakers, implantable defibrillators, heart valves, ablation systems, and vascular stents. In FY25, it generated $12.4 billion in revenue (37.2% of total revenue), growing 5.5%. Medtronic continues to lead in innovations like leadless pacing and pulsed field ablation, addressing both chronic and acute cardiac conditions globally. • Cardiac Rhythm & Heart Failure (CRHF): CRHF focuses on devices tha manage abnormal heart rhythms and heart failure. It includes pacemakers like the Micra leadless system, implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, and insertable cardiac monitors. The segment also includes cardiac ablation systems and remote monitoring services.• Structural Heart & Aortic (SHA): SHA provides solutions for heart valve disorders and aortic diseases. It includes transcatheter aortic valve replacement (TAVR) systems like Evolut FX, surgical heart valves, perfusion systems, and endovascular stent grafts. These devices are used in both minimally invasive and open-heart procedures.• Coronary & Peripheral Vascular (CPV): CPV delivers therapies for coronary artery disease and peripheral vascular conditions. It includes druge luting stents (e.g., Onyx Frontier), angioplasty balloons, renal denervation systems (e.g., Symplicity Spyral), and venous disease treatments like VenaSeal. Neuroscience: The Neuroscience segment addresses neurological and musculoskeletal disorders through surgical and therapeutic technologies. It includes Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation. This segment integrates robotics, AI, and navigation systems to improve surgical precision and patient outcomes. In FY25, it generated $9.8 billion in revenue (29.4% of total revenue), growing 4.7%. Medtronic's innovations in spine surgery, stroke treatment, and neuromodulation continue to drive global adoption. • Cranial & Spinal Technologies (CST): CST develops surgical solutions for spine and cranial procedures. It includes implants, biologics, and enabling technologies like Mazor robotics, StealthStation navigation, and UNiD AI-driven planning. These tools help surgeons perform complex procedures with greater accuracy.• Specialty Therapies: This subsegment includes neurovascular, ENT (ear, nose, and throat), and pelvic health therapies. It offers stroke treatment devices like Solitaire and Pipeline, sinus implants like Propel, and bladder control systems like InterStim. These minimally invasive solutions address critical conditions and improve quality of life.• Neuromodulation: Neuromodulation provides implantable systems for managing chronic pain, movement disorders, and epilepsy. It includes spinal cord stimulators (e.g., Intellis, Inceptiv), deep brain stimulation (e.g., Percept), and drug infusion pumps (e.g., SynchroMed). These technologies personalize therapy using real-time Surgical: The Medical Surgical segment supports hospitals and surgical centers with advanced tools and monitoring systems. It includes Surgical & Endoscopy and Acute Care and Acute Care & Monitoring sub-segments. This segment offers robotic-assisted surgery, AI-powered endoscopy, and patient monitoring solutions. In FY25, it generated $8.4 billion in revenue (25.1% of total revenue), a decrease of 0.1%.• Surgical & Endoscopy (SE): SE provides advanced surgical instruments and digital surgery platforms. It includes stapling systems (e.g., Tri-Staple), vessel sealers (e.g., LigaSure), robotic-assisted surgery (Hugo RAS), and AI-powered endoscopy (GI Genius). These tools enhance surgical precision and efficiency.• Acute Care & Monitoring (ACM): ACM focuses on patient monitoring and respiratory care. It includes pulse oximetry (Nellcor), capnography (Microstream), airway management (Shiley), and brain monitoring (BIS). These solutions help clinicians manage critical care and reduce complications. Diabetes: The Diabetes segment is dedicated to managing Type 1 and Type 2 diabetes through smart, connected technologies. It includes insulin pumps (e.g., MiniMed 780G), continuous glucose monitoring (CGM) systems (e.g., Guardian), and smart insulin pens (e.g., InPen). In FY25, the segment generated $2.8 billion in revenue (8.2% of total revenue), growing 10.7%. Medtronic's diabetes solutions aim to automate insulin delivery and simplify disease management. The MiniMed 780G system features SmartGuard technology, which adjusts insulin every 5 minutes and includes a meal detection algorithm. The Guardian CGM system provides real-time glucose data, while the InPen smart pen integrates with CGM to guide dosing. Medtronic is focused on expanding access to automated insulin delivery systems and competing with pharmaceutical alternatives by emphasizing long-term glycemic control and patient empowerment. Revenue Trend and Adjusted Operating Profit vs. Margin Trend 4Q25 Total revenue grew by 3.9% YoY to $8.9 billion (+1.1% vs. consensus), driven by strong performance in Cardiovascular and Diabetes segments. International markets and new product launches made significant contributions to the growth. Cardiovascular segment revenue grew 6.6% YoY to $3.3 billion, driven by a 9.2% YoY increase in the Cardiac Rhythm & Heart Failure segment, a 6.9% YoY increase from the Structural Heart & Aortic segment, offset by a 0.2% YoY decline in the Coronary & Peripheral Vascular segment. Neuroscience segment revenue increased 2.9% YoY to $2.6 billion, driven by a 4.0% YoY increase in the Cranial & Spinal Technologies segment, a 9.5% YoY increase in the Neuromodulation segment, offset by a 2.4% YoY decline in the Specialty Therapies segment. Medical Surgical segment revenue improved 0.6% YoY to $2.2 billion, driven by a 0.2% YoY increase in the Surgical & Endoscopy segment, and a 6.3% YoY increase in the Acute Care & Monitoring segment. Diabetes segment revenue grew 10.3% YoY to $728.0 million, driven by strong US adoption of the MiniMed 780G system with high Continuous Glucose Monitor attachment and international pump upgrades to the Simplera Sync sensor. Adjusted operating income grew 7.6% YoY to $2.5 billion (-0.3% vs. consensus), and the corresponding margin improved ~94 bps to 27.8%, driven by strong revenue growth across key portfolios and disciplined expense management. Operating leverage from higher sales and lower SG&A as a percentage of revenue also contributed to margin expansion. Adjusted net income increased 7.8% YoY to $2.1 billion (+2.7% vs. consensus), and the corresponding margin grew ~84 bps to 23.3%. Adjusted diluted earnings per share came in at $1.62 (4Q24: $1.46), beating the consensus estimates by 2.7%. 4Q25 Revenue FY25 Total revenue grew by 3.6% to $33.5 billion (+0.1% vs. consensus), driven by strong performance in Cardiovascular and Diabetes segments, with notable growth in Cardiac Ablation. Continued innovation, international expansion, and new product approvals also supported overall growth. Cardiovascular segment revenue grew 5.5% to $12.5 billion, driven by a 6.6% increase in the Cardiac Rhythm & Heart Failure segment, a 2.3% increase from the Coronary & Peripheral Vascular segment, offset by a 0.1% decline in the Structural Heart & Aortic segment. Neuroscience segment revenue increased 4.7% to $9.9 billion, driven by a 4.6% increase in the Cranial & Spinal Technologies segment, a 10.7% increase in the Specialty Therapies segment, and a 1.2% growth in the Neuromodulation segment. Medical Surgical segment revenue declined 01% to $8.4 billion, due to 0.2% decline in the Surgical & Endoscopy segment, and offset by 0.1% growth in the Acute Care & Monitoring segment. Diabetes segment revenue grew 10.7% to $2.7 billion. Adjusted operating income grew 4.5% to $8.6 billion (in line with consensus), and the corresponding margin improved ~23 bps to 25.8%, driven by strong revenue growth and lower SG&A expenses. Adjusted net income increased 2.3% to $7.1 billion (+0.8% vs. consensus), while the corresponding margin contracted ~27 bps to 21.1%. Adjusted diluted earnings per share came in at $5.49 (FY24: $5.20), beating the consensus estimates by 0.6%. FY25 Revenue Company DescriptionMedtronic plc (Parent) Medtronic plc, headquartered in Galway, Ireland, is the world's leading healthcare technology company, committed to alleviating pain, restoring health, and extending life. With over 95,000 employees across more than 150 countries, Medtronic delivers innovative solutions for more than 70 health conditions. The company operates through four primary segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. These segments encompass a wide range of technologies, including cardiac rhythm devices, spinal and brain therapies, surgical tools, and insulin delivery systems. New Diabetes Company (Spin-Off) The New Diabetes Company will emerge as a leading global direct-to-consumer diabetes care provider, uniquely offering a comprehensive ecosystem for intensive insulin management. With a portfolio that includes insulin pumps, continuous glucose monitoring (CGM) systems, and digital health solutions, it empowers individuals to manage diabetes with greater ease and freedom. Backed by a dedicated team of over 8,000 employees and a robust global infrastructure, the company is poised to accelerate innovation in Automated Insulin Delivery and Smart Multiple Daily Injections (MDI). Organization Structure
Yahoo
4 days ago
- Yahoo
Bango 2024 Full Year Results and Outlook
CAMBRIDGE, United Kingdom, June 06, 2025 (GLOBE NEWSWIRE) -- Bango (AIM: BGO), today announces its full year results for the 12 months ended 31 December 2024 and provides an update on current trading and outlook for 2025. FY24 Financial Overview: Results for the 12 months ended 31 December 2024 FY24 FY23 YoY Change Transactional Revenue1 $36.2M $32.7M +11% DVM & One Off Revenue2 $17.2M $13.4M +28% Total Revenue $53.4M $46.1M +16% Annual Recurring Revenue (ARR) 3 $14.0M $8.8M +59% Net Retention4 125% 137% Adjusted EBITDA5 $15.3M $6.4M +139% Loss After Tax ($3.7M) ($8.8M) $5.1M Net (debt)/cash at 31 December6 ($1.8M) ($4.0M) $2.2M FY24 Operational highlights: 9 new Digital Vending Machine® (DVMTM) license customers (total 27 at end of 2024) 110 content providers connected to the DVM, up from 93 at the end of 2023 Launched Disney+ with Continente - Portugal's largest high-street retailer, in only 12 weeks from first customer contact First two DVM CX (user interface) customers signed, including Altice in the US First Eastern European DVM customer signed Post period-end Digital Vending Machine® 6 new DVM customers to date in 2025, including: New US wins mean the Bango DVM now serves 6 out of the top 8 US communication providers (by subscriber count) First DVM customer in South Korea – leading Telco selected Bango DVM for bundling New DVM Telco customer in Benelux marks the first win from an improved Western Europe DVM pipeline First customer launch of the Bango DVM CX (user interface) with Altice in the US. The DVM CX reduces the effort for resellers when launching bundled offers, allowing them to launch much faster. It is sold as an additional license fee. DVM is on track to once again deliver double digit revenue growth in-line with consensus7. Transactional 98% of traffic acquired with DOCOMO Digital has been migrated to the Bango platform The high cost of sales routes acquired from DOCOMO Digital have experienced volatility and are below expectation however, given the margin profile of these routes, there is minimal impact to EBITDA. Work to optimize or restructure these routes is ongoing. Bango has disconnected several small, unprofitable routes since the DOCOMO Digital acquisition and continues to launch selected new routes where there is significant growth potential. Core Transactional revenue (excluding the high cost of sales routes) is in-line with expectations. Financing Bango has secured financing which will be used to strengthen the balance sheet and provide further flexibility on the timing of cost reductions. Bango has secured an enhanced loan facility from NHN. Under the agreement, the existing loan will increase by $2.85M and include a deferral of principal repayments for 18 months (further information can be found detailed in the RNS announcement published earlier today titled, 'Loan Agreement and Related Party Transaction'). In addition, Bango has secured a $15M Revolving Credit Facility (RCF) with NatWest. This provides a committed, long-term financing solution that will replace the existing £3M overdraft from Barclays. Efficiency Initiatives Bango expects to report FY25 Adj. EBITDA in-line with consensus7 Further efficiencies are expected to result in a modest increase to Adj. EBITDA vs consensus7 in FY26 of $1M. A reduction in R&D capital expenditure versus current consensus7, of $0.5M in FY25 and $1M in FY26 is planned. Board changes As separately announced, (See 'Directorate Change' RNS published today), Anil Malhotra and Frank Bury will formally step down from the Board at the conclusion of the AGM on 30 June 2025. Investor Presentation: Bango is hosting a presentation, open to all existing and potential shareholders, at 10.30am BST today. Investors can sign up to Investor Meet Company for free and register to join the call here: Bango CEO, Paul Larbey, said: '2024 was a pivotal year for Bango, marked by strong revenue growth, a significant increase in profitability, and strategic progress across both our Digital Vending Machine® and Payments businesses. We delivered a 16% increase in total revenue and more than doubled Adjusted EBITDA to $15.3M, reflecting the operational leverage of our platform and disciplined cost management. The DVM continues to gain global traction, with 9 new customers added during the year and a strong pipeline rapidly converting in 2025 with 6 new wins including our first customer in South Korea. With tens of millions of subscriptions already managed, and the scalability to support hundreds of millions more, Bango is uniquely placed to benefit from the structural shift toward subscription-based services and indirect distribution models. Increasingly, the Bango DVM is becoming the standard platform for subscription bundling - not just in capability, also in reputation. It's the solution recommended by some of the world's largest content providers when their partners want to scale subscriptions and build customer engagement, and now serves 6 of the top 8 US communication service providers. This positions Bango at the very heart of the global subscription economy. In the Payments business, Bango continues to have a leading position in the market and remains the largest Direct Carrier Billing partner for the Google Play store, the only partner powering DCB for the Amazon store in Japan and the sole provider of online DCB services to NTT DOCOMO Japan - the largest operator, in the most valuable DCB market. With the migration of traffic from the DOCOMO Digital platform to the Bango platform we are optimizing our Payments business for cash and profitability by simplifying operations. The financing provided by NatWest and NHN demonstrate strong confidence in Bango's business model & strategic plan and materially strengthens the balance sheet. The decision to make the strategic investment in DVM coupled with the market growth in 'Super bundling' are driving a strong sales pipeline. This combined with disciplined cost management, a reduction in R&D capex and the inherent operational leverage of our platform will deliver a step-change in cash generation in FY26 and drive shareholder returns. We view the future opportunity with both confidence and excitement.' See the full RNS announcement: Notes: The Annual Report, including full accounts, is available at, and will be sent to shareholders shortly. 1 Transactional Revenue is revenue derived by charging a percentage of the retail price paid by the consumer and is made up of carrier billing, resale and e-Disti revenue share amounts.2 DVM & One Off Revenue includes all DVM license and support fees, revenue from Bango Audiences (discontinued in Q1 FY24) and one off fees including DVM set-up and change requests. 3Annual Recurring Revenue is the expected annual revenues to be generated in the next 12 monthsbased on contracted revenues recognized as at 31 December.4 Net Retention is a measure of the retention and expansion of revenue from existing customers over a specific period and is calculated by dividing the ARR from existing customers at the end of a period by the ARR generated from those same customers at the beginning of the period.5Adjusted EBITDA is earnings before interest, tax, depreciation, amortization, negative goodwill, exceptional items and share based payment charge.6Net debt is cash and cash equivalents plus short-term investments less loans and borrowings. 7Current consensus market expectations prior to today's announcement. The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No.596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain. The person responsible for making this announcement on behalf of Bango is Paul Larbey, Chief Executive Officer. For further information, please contact: Investor questions on this announcementWe encourage all investors to share questionson this announcement via our investor hub About Bango Bango enables content providers to reach more paying customers through global partnerships. Bango revolutionized the monetization of digital content and services, by opening-up online payments to mobile phone users worldwide. Today, the Digital Vending Machine® is driving the rapid growth of the subscriptions economy, powering choice and control for subscribers. The world's largest content providers, including Amazon, Google and Microsoft trust Bango technology to reach subscribers everywhere. Bango, where people subscribe. For more information, visit Subscribe to our news alert service:
Yahoo
5 days ago
- Yahoo
TOP Ships Inc. Announces Ex-Distribution Date for Planned Spin-Off of Rubico, a New Nasdaq-Listed Suezmax Tanker Company
ATHENS, Greece, June 05, 2025 (GLOBE NEWSWIRE) -- TOP Ships Inc. (the 'Company' or 'TOP Ships') (NYSE American:TOPS), an international owner and operator of modern, fuel-efficient 'ECO' tanker vessels, announced today that the NYSE American (the 'NYSE') has established an ex-distribution date for the previously-announced proposed spin-off of two of its Suezmax tanker vessels. Rubico Inc. ('Rubico'), currently a subsidiary of TOP Ships, would become an independent publicly-traded company listed on the Nasdaq Capital Market as a result of the planned spin-off. The initial assets of Rubico will be the M/T Eco Malibu and M/T Eco West Coast, each a modern, high specification, scrubber-fitted and fuel-efficient 157,000 dwt Suezmax tanker. As part of the spin-off transaction, TOP Ships intends to distribute 100% of the common shares of Rubico pro rata to its securityholders of record as of June 16, 2025. The NYSE has established an ex-distribution date for the distribution of Rubico common shares of June 16, 2025. Beginning on that date, TOP Ships common shares will trade without an entitlement by the purchaser of such shares to Rubico common shares distributed in connection with the spin-off. TOP Ships securityholders do not need to take any action to receive Rubico shares to which they are entitled, and do not need to pay any consideration or surrender or exchange TOP Ships common shares or warrants. TOP Ships expects that approximately 3,057,337 Rubico common shares will be distributed in the Spin-Off at an assumed distribution ratio of one Rubico common share for every two TOP Ships common shares held by TOP Ships common shareholders (and warrantholders on an as-exercised basis) at the close of business on June 16, 2025. However, such distribution ratio will depend on the number of TOP Ships common shares outstanding, as well as the number of common shares into which outstanding TOP Ships common stock purchase warrants are exercisable, on June 16, 2025, the record date for the spin-off distribution. Concurrently and conditioned on the spin-off transaction, Rubico expects to raise $1.5 million in a private placement of its common shares at a purchase price of $20.00 per share. Rubico has filed a registration statement on Form 20-F with the Securities and Exchange Commission in connection with the proposed spin-off. The transaction remains subject to such registration statement being declared effective and the approval of the listing of Rubico's common shares on the Nasdaq Capital Market. There can be no assurance that the transaction will occur or, if it does occur, of its terms or timing. TOP Ships may, at any time, decide to abandon the spin-off. A copy of the registration statement on Form 20-F filed by Rubico is available at The information in the filed registration statement on Form 20-F is not final and remains subject to change. About TOP Ships Inc. TOP Ships Inc. is an international owner and operator of ocean-going vessels focusing on modern, fuel-efficient eco tanker vessels transporting crude oil, petroleum products (clean and dirty) and bulk liquid chemicals. For more information about TOP Ships Inc., visit its website: Cautionary Note Regarding Forward-Looking Statements Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts, including statements regarding the proposed spin-off and the prospects and strategies of TOP Ships and Rubico following the spin-off, the valuation of the shares of Rubico and TOP Ships following the spin-off, and the listing of Rubico's common shares on the Nasdaq Capital Market. The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words 'believe,' 'anticipate,' 'intends,' 'estimate,' 'forecast,' 'project,' 'plan,' 'potential,' 'may,' 'should,' 'expect,' 'pending,' and similar expressions identify forward-looking statements. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including, without limitation, our management's examination of historical operating trends, data contained in our records, and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs, or projections. Please see our filings with the Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties. The information set forth herein speaks only as of the date hereof, and we disclaim any intention or obligation to update any forward‐looking statements as a result of developments occurring after the date of this communication. For further information please contact: Alexandros TsirikosChief Financial OfficerTOP Ships +30 210 812 8107Email: atsirikos@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
